ProCE Banner Activity

An Interactive Treatment Decision Tool for HER2-Negative Early Breast Cancer

Clinical Thought
Read this expert commentary for an overview of our new treatment decision support tool for HER2 negative early breast cancer, which provides treatment recommendations from 5 breast cancer experts for your patients with HER2 negative early breast cancer.

Released: September 07, 2022

Expiration: September 06, 2023

Share

Faculty

Kevin Kalinsky

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Lilly

Merck Sharp & Dohme Corp.

Partners

Smart Patients

ProCE Banner

Faculty Disclosure

Primary Author

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Kevin Kalinsky, MD, MS: consultant, advisor, speaker: 4D Pharma, AstraZeneca, Cyclocel, Daichi Sankyo, Immunomedics, Lilly, Merck, Mersana, Novartis, Oncosec, Pfizer, Puma, Seattle Genetics.